Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab.

IF 2.7 4区医学 Q3 IMMUNOLOGY Immunotherapy Pub Date : 2024-08-19 DOI:10.1080/1750743X.2024.2385881

Alessandra Damassi, Malvina Cremante, Alessio Signori, Sara Elena Rebuzzi, Andrea Malgeri, Marilena Di Napoli, Orazio Caffo, Francesca Vignani, Alessia Cavo, Giandomenico Roviello, Veronica Prati, Marianna Tudini, Francesco Atzori, Marco Messina, Franco Morelli, Giuseppe Prati, Franco Nolè, Fabio Catalano, Veronica Murianni, Pasquale Rescigno, Giuseppe Luigi Banna, Giuseppe Fornarini, Sebastiano Buti

{"title":"Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab.","authors":"Alessandra Damassi, Malvina Cremante, Alessio Signori, Sara Elena Rebuzzi, Andrea Malgeri, Marilena Di Napoli, Orazio Caffo, Francesca Vignani, Alessia Cavo, Giandomenico Roviello, Veronica Prati, Marianna Tudini, Francesco Atzori, Marco Messina, Franco Morelli, Giuseppe Prati, Franco Nolè, Fabio Catalano, Veronica Murianni, Pasquale Rescigno, Giuseppe Luigi Banna, Giuseppe Fornarini, Sebastiano Buti","doi":"10.1080/1750743X.2024.2385881","DOIUrl":null,"url":null,"abstract":"Aim: To define the prognostic significance of first-line TKI in mRCC patients receiving nivolumab.Materials and methods: A total of 571 mRCC patients who received ≥second line nivolumab were included in this subanalysis. The correlation between prior TKI (sunitinib vs. pazopanib) and overall response rate (ORR), disease control rate, progression-free survival and overall survival were investigated. Additionally, the impact of TKI choice according to the International Metastatic RCC Database Consortium prognostic score was examined.Results: There was no significant difference between sunitinib and pazopanib groups in terms of mPFS, mOS, overall response rate and disease control rate. Moreover, no difference between sunitinib and pazopanib was found according to the International Metastatic RCC Database Consortium prognostic score.Conclusion: There is no conclusive evidence favoring pazopanib or sunitinib treatment before initiating nivolumab therapy in metastatic renal cell carcinoma patients.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2024.2385881","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To define the prognostic significance of first-line TKI in mRCC patients receiving nivolumab.Materials and methods: A total of 571 mRCC patients who received ≥second line nivolumab were included in this subanalysis. The correlation between prior TKI (sunitinib vs. pazopanib) and overall response rate (ORR), disease control rate, progression-free survival and overall survival were investigated. Additionally, the impact of TKI choice according to the International Metastatic RCC Database Consortium prognostic score was examined.Results: There was no significant difference between sunitinib and pazopanib groups in terms of mPFS, mOS, overall response rate and disease control rate. Moreover, no difference between sunitinib and pazopanib was found according to the International Metastatic RCC Database Consortium prognostic score.Conclusion: There is no conclusive evidence favoring pazopanib or sunitinib treatment before initiating nivolumab therapy in metastatic renal cell carcinoma patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

接受 nivolumab 治疗的转移性肾细胞癌患者既往 TKI 类型的预后价值。

目的：明确接受尼夫单抗治疗的mRCC患者一线TKI的预后意义：本子分析共纳入了571例接受≥二线nivolumab治疗的mRCC患者。研究了既往TKI（舒尼替尼与帕唑帕尼）与总反应率（ORR）、疾病控制率、无进展生存期和总生存期之间的相关性。此外，还研究了根据国际转移性RCC数据库联盟预后评分选择TKI的影响：结果：舒尼替尼组和帕唑帕尼组在mPFS、mOS、总反应率和疾病控制率方面无明显差异。此外，根据国际转移性 RCC 数据库联盟的预后评分，舒尼替尼和帕唑帕尼之间也没有差异：结论：对于转移性肾细胞癌患者来说，没有确凿证据支持在开始尼伐单抗治疗前使用帕唑帕尼或舒尼替尼。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.